Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Coinbase Indicates $380

-Reuters

byMichael Horton

April 14, 2021

1 minute read

-Reuters

Legal
News

Agenus Granted U.S. Patent Titled ‘Anti-GITR antibodies and methods of use thereof’

By Benzinga Newsdesk

Today, 7:40 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=4671&f=G&l=50&d=PTXT&p=94&S1=20220802&OS=20220802&RS=2022080

AGEN

BMO Capital Initiates Coverage On Genmab with Market Perform Rating, Announces Price Target of $34.73

By Benzinga Newsdesk

Today, 7:40 AM

BMO Capital analyst Etzer Darout initiates coverage on Genmab (NASDAQ:GMAB) with a Market Perform rating and announces Price Target of $34.73.

GMAB

Penumbra Q2 Earnings Beat Estimates; Raises FY21 Sales Outlook

By Vandana Singh

Today, 7:40 AM

Penumbra Inc (NYSE:PEN) reported Q2 sales of $184.3 million, an increase of 75.3% Y/Y, or 72.7% on a constant currency…

PEN

Citigroup Downgrades Syneos Health to Neutral, Lowers Price Target to $105

By Benzinga Newsdesk

Today, 7:40 AM

Citigroup analyst Patrick Donnelly downgrades Syneos Health (NASDAQ:SYNH) from Buy to Neutral and lowers the price target from $115 to $105.

SYNH

Coinbase Indicates $380

Related Posts

Agenus Granted U.S. Patent Titled ‘Anti-GITR antibodies and methods of use thereof’

BMO Capital Initiates Coverage On Genmab with Market Perform Rating, Announces Price Target of $34.73

Penumbra Q2 Earnings Beat Estimates; Raises FY21 Sales Outlook

Citigroup Downgrades Syneos Health to Neutral, Lowers Price Target to $105